El Cheikh Jean, Bidaoui Ghassan, Sharrouf Layal, Zahreddine Ammar, Massoud Radwan, Nehme Rita, Kreidieh Nabila, Moukalled Nour, Abou Dalle Iman, Mahfouz Rami, Bazarbachi Ali
Division of Hematology/Oncology, Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon.
Bone Marrow Transplantation Program, Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon.
Front Transplant. 2023 Jun 12;2:1149393. doi: 10.3389/frtra.2023.1149393. eCollection 2023.
This letter describes the experience of the American University of Beirut Medical Center in Lebanon with haploidentical stem cell transplant (haplo-SCT) for hematological malignancies in adult patients. Haplo-SCT made it possible through universal and rapid donor availability for most of the adult patients with leukemia or lymphoma not only in the Middle East but also globally. Moreover, the use of post-transplant cyclophosphamide (PTCy) and reduced intensity conditioning (RIC) regimens when indicated improved the outcome and decreased the toxicity of haploidentical stem cell transplant.RIC regimens also allowed its use in the elderly population. Patients from throughout the Middle East come to our center, the American university of Beirut Medical Center, to receive this transformative type of stem cell transplant. In this paper, we discuss the results of haplo-SCT with PTCy done on adult patients with hematological malignancies in our center from 2015 to 2021. The results are encouraging and show that haplo-SCT should be considered more often in the Middle Eastern countries. The subgroup analysis showed the importance of achieving complete remission of the disease prior to transplant to improve outcomes in our center. There is a paucity of literature on the outcomes of haplo-SCT in the Middle East which may contribute to the limited number of centers that offer this type of SCT. Herein, we aim to fill this gap in the hopes of encouraging the implementation of this potentially curative modality of treatment to a larger extent in the Middle East.
这封信描述了黎巴嫩贝鲁特美国大学医学中心对成年血液系统恶性肿瘤患者进行单倍体干细胞移植（haplo-SCT）的经验。单倍体干细胞移植通过为大多数白血病或淋巴瘤成年患者普遍且快速地提供供体，不仅在中东地区，而且在全球范围内成为可能。此外，在适当的时候使用移植后环磷酰胺（PTCy）和减低强度预处理（RIC）方案改善了单倍体干细胞移植的结果并降低了毒性。RIC方案也使其能够应用于老年人群。来自中东各地的患者来到我们中心，即贝鲁特美国大学医学中心，接受这种变革性的干细胞移植。在本文中，我们讨论了2015年至2021年在我们中心对成年血液系统恶性肿瘤患者进行的采用PTCy的单倍体干细胞移植的结果。结果令人鼓舞，表明在中东国家应更频繁地考虑单倍体干细胞移植。亚组分析表明，在我们中心，移植前实现疾病完全缓解对于改善结果很重要。关于中东地区单倍体干细胞移植结果的文献很少，这可能导致提供这种类型干细胞移植的中心数量有限。在此，我们旨在填补这一空白，希望鼓励在更大程度上在中东地区实施这种潜在的治愈性治疗方式。
